NEW YORK, Sept 21 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) said on Friday that U.S. health regulators stopped short of approving a new long-acting version of its widely used epilepsy drug, Lamictal, until certain concerns are addressed.
